179 related articles for article (PubMed ID: 24529133)
1. Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance?
Li N; Fu J; Koonen DP; Kuivenhoven JA; Snieder H; Hofker MH
Atherosclerosis; 2014 Mar; 233(1):130-8. PubMed ID: 24529133
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
[TBL] [Abstract][Full Text] [Related]
3. Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles.
Ståhlman M; Fagerberg B; Adiels M; Ekroos K; Chapman JM; Kontush A; Borén J
Biochim Biophys Acta; 2013 Nov; 1831(11):1609-17. PubMed ID: 23896361
[TBL] [Abstract][Full Text] [Related]
4. Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets.
Ng DS
Can J Diabetes; 2013 Oct; 37(5):319-26. PubMed ID: 24500559
[TBL] [Abstract][Full Text] [Related]
5. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
6. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
Adiels M; Olofsson SO; Taskinen MR; Borén J
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
[TBL] [Abstract][Full Text] [Related]
7. [Atherogenic dyslipidemia and the metabolic syndrome: pathophysiological mechanisms].
Zák A; Slabý A
Cas Lek Cesk; 2008; 147(9):459-70. PubMed ID: 18988488
[TBL] [Abstract][Full Text] [Related]
8. Metabolic syndrome: is it a syndrome? Does it matter?
Kahn R
Circulation; 2007 Apr; 115(13):1806-10; discussion 1811. PubMed ID: 17404171
[No Abstract] [Full Text] [Related]
9. A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
Malloy MJ; Kane JP
Adv Intern Med; 2001; 47():111-36. PubMed ID: 11795072
[TBL] [Abstract][Full Text] [Related]
10. Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome.
Mehta A
Postgrad Med; 2010 May; 122(3):61-70. PubMed ID: 20463415
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
Reaven GM
Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
[TBL] [Abstract][Full Text] [Related]
12. Does statin monotherapy address the multiple lipid abnormalities in type 2 diabetes?
Shepherd J
Atheroscler Suppl; 2005 Sep; 6(3):15-9. PubMed ID: 16046280
[TBL] [Abstract][Full Text] [Related]
13. Dyslipidemia in the metabolic syndrome: clinical implications and management.
Hafidh SA; Lavie CJ; Burns BP; Khan SS; Alpert MA
Minerva Cardioangiol; 2006 Apr; 54(2):215-27. PubMed ID: 16778753
[TBL] [Abstract][Full Text] [Related]
14. Cardiology patient page. The metabolic syndrome.
Lennie TA
Circulation; 2006 Oct; 114(15):e528-9. PubMed ID: 17030691
[No Abstract] [Full Text] [Related]
15. [Dyslipoproteinemia and metabolic syndrome. Effects of insulin resistance and hyperinsulinemia on lipid metabolism].
Krone W; Müller-Wieland D; Wirth H
Fortschr Med; 1992 Dec; 110(34):645-8. PubMed ID: 1483617
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus.
Reyes-Soffer G; Rondon-Clavo C; Ginsberg HN
Expert Opin Pharmacother; 2011 Jun; 12(9):1429-38. PubMed ID: 21426238
[TBL] [Abstract][Full Text] [Related]
17. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
Turhan H; Yetkin E
Int J Cardiol; 2006 Jun; 110(2):276-7. PubMed ID: 16364471
[TBL] [Abstract][Full Text] [Related]
18. [Lipid management--treatment goal and strategy].
Koshiyama H
Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
[TBL] [Abstract][Full Text] [Related]
19. [Metabolic syndrome and diabetes mellitus].
Nihon Rinsho; 2013 Sep; 71(9):1611-7. PubMed ID: 24205723
[TBL] [Abstract][Full Text] [Related]
20. Catabolism of lipoproteins and metabolic syndrome.
Therond P
Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
